

## Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022

October 20, 2022

EMERYVILLE, Calif., Oct. 20, 2022 /PRNewswire/ -- <u>Dynavax Technologies Corporation</u> (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022, after the U.S. financial markets close.



Dynavax will host a conference call and live audio webcast on Thursday, November 3, 2022, at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at <a href="https://investors.dvnavax.com/events-presentations">https://investors.dvnavax.com/events-presentations</a>. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the <u>caller registration link</u>. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

## **About Dynavax**

Dynavax is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit <a href="https://www.dvnavax.com">www.dvnavax.com</a> and follow Dynavax on <a href="https://www.dvnavax.com">LinkedIn</a>.

## Contacts:

Nicole Arndt Investor Relations and Corporate Communications narndt@dynavax.com 510-665-7264

Derek Cole, President Investor Relations Advisory Solutions derek.cole@IRadvisory.com

C View original content to download multimedia: <a href="https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-financial-results-and-host-conference-call-on-november-3-2022-301655383.html">https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-financial-results-and-host-conference-call-on-november-3-2022-301655383.html</a>

SOURCE Dynavax Technologies